Summary:
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy (maintenance of remission) and safety of etrolizumab compared with placebo in patient with moderate to severe active ulcerative colitis who are naïve to TNF inhibitors
Qualified Participants Must:
• Be between 18 and 80 years of age (inclusive)
•
Have moderate to severe active ulcerative colitis (UC)
•
Be naїve to treatment with any anti-TNF therapy
•
Have a previous immunosuppressant/corticosteroid treatment history
•
Have evidence of UC extending a minimum of 20 cm from the anal verge
•
Have no past or present ileostomy or colostomy
•
Not have a diagnosis of Cohn’s disease
Qualified Participants May Receive:
$50.00 for each completed visit for taking part in this study. You will not be charged for etrolizumab while you are participating in this study. Also, all procedures that are required only for this study and that are not part of your regular medical care will be provided to you at no charge.